The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex with men.
Guidance: Standard Operating Procedures for Addressing Partner Relationships and Gender-Based Violence in Pre-Exposure Prophylaxis (PrEP) Services
Standard Operating Procedure Guidance Evidence has shown that intimate partner violence (IPV) may act as a barrier to accessing HIV services, including PrEP services. IPV is associated with lower PrEP uptake and adherence and increased PrEP interruption among cisgender women. Although cisgender women have made up the majority of participants in research on PrEP and…
Implementation Study Tracker
This study tracker, produced under the BioPIC platform, reflects all currently known activities relating to landscaping, product introduction, introduction studies, and implementation research for new biomedical PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the tracker, please contact Catherine Verde Hashim to ensure they…
New PrEP Product Implementation Roadmap for PrEP vaginal ring and CAB for PrEP in Uganda
This presentation outlines the timelines for implementation of the dapivirine vaginal ring and cabotegravir (CAB) for PrEP in Uganda.
Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (French)
The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…
Coordinating Implementation Science for CAB for PrEP: Focus on Research and Surveillance during Pregnancy and Breastfeeding
These notes outline the key takeaways of a Think Tank focussing on CAB for PrEP implementation research and surveillance during pregnancy and breastfeeding. The Think Tank was part of an ongoing series by BioPIC and the WHO on coordinating implementation science for injectable CAB for PrEP.
RISE CAB for PrEP Training Toolkit
With the release of the WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention in 2022, HIV prevention programs and implementing partners are working to prepare for rapid expansion of additional methods of HIV pre-exposure prophylaxis (PrEP). Experience from the scale-up of previous HIV prevention programs demonstrates the advantages of ready-made provider capacity building resources…
Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
This article from AIDS and Behavior describes the results of a discrete choice experiment on preferences for oral or injectable PrEP amongst gay, bisexual, and other men who have sex with men in the USA, including mode of administration, side-effects, monetary cost, and time cost.
HIV Prevention User Journey Tool
The HIV Prevention Journey Tool was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. The digital tool, which has been optimized for use on mobile devices, can be accessed here.…
An Update on Expanding HIV Preexposure Prophylaxis
This article from the Journal of the American Academy of Physicians Assistants describes how to better employ PrEP in the United States in light of changes to the Centers for Disease Control guidelines on PrEP counselling, monitoring, and delivery, and approval of injectable cabotegravir for PrEP by the US Food and Drug Administration.
Estimating the Impact of HIV PrEP Regimens Containing Long-acting Injectable Cabotegravir or Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine among Men who Have Sex with Men in the United States: A mathematical modelling study for HPTN 083
This article from The Lancet Regional Health- Americas describes the results of a modelling exercise which compares the potential population-level impact of oral PrEP (TDF/FTC) and Cabotegravir for PrEP among gay and bisexual men who have sex with men in Atlanta, Georgia, USA.